Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Recruiting · NCT06581562 · Registry updated 2024-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. | Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, arthritic joint disease, arthropathy, autoimmune disease, cardiovascular disorder, connective tissue disorder, granulomatosis with polyangiitis, immune system disorder, interstitial lung disease, lung disorder, musculoskeletal system disorder, necrotizing vasculitis, pemphigus, pemphigus vulgaris, respiratory system disorder, rheumatic disorder, rheumatoid arthritis, skin disorder, skin vascular disease, systemic lupus erythematosus, vascular disorder, vasculitis, vesiculobullous skin disease | Recruiting | Phase 1 | 2024-09-03 | NCT06581562 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Artiva Biotherapeutics, Inc. | 4 |
| IRIS Research and Development, LLC | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| IRIS Research and Development, LLC | Plantation | United States | 2 |